Journal
BMC CANCER
Volume 21, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12885-021-08186-9
Keywords
PX-478; HIF-1 alpha; inhibition; Dichloroacetate; Synergism; Cancer therapy; Drug combination; Cancer cell lines; Metabolism
Categories
Funding
- Berlin Institute of Health
Ask authors/readers for more resources
The combination of dichloroacetate (DCA) and the HIF-1 alpha inhibitor PX-478 exhibited synergistic effects in various cancer cell lines, inhibiting cell proliferation through increased generation of reactive oxygen species and induction of apoptosis. These findings suggest the potential significance of combining these two compounds for further research and clinical trials.
Background One key approach for anticancer therapy is drug combination. Drug combinations can help reduce doses and thereby decrease side effects. Furthermore, the likelihood of drug resistance is reduced. Distinct alterations in tumor metabolism have been described in past decades, but metabolism has yet to be targeted in clinical cancer therapy. Recently, we found evidence for synergism between dichloroacetate (DCA), a pyruvate dehydrogenase kinase inhibitor, and the HIF-1 alpha inhibitor PX-478. In this study, we aimed to analyse this synergism in cell lines of different cancer types and to identify the underlying biochemical mechanisms. Methods The dose-dependent antiproliferative effects of the single drugs and their combination were assessed using SRB assays. FACS, Western blot and HPLC analyses were performed to investigate changes in reactive oxygen species levels, apoptosis and the cell cycle. Additionally, real-time metabolic analyses (Seahorse) were performed with DCA-treated MCF-7 cells. Results The combination of DCA and PX-478 produced synergistic effects in all eight cancer cell lines tested, including colorectal, lung, breast, cervical, liver and brain cancer. Reactive oxygen species generation and apoptosis played important roles in this synergism. Furthermore, cell proliferation was inhibited by the combination treatment. Conclusions Here, we found that these tumor metabolism-targeting compounds exhibited a potent synergism across all tested cancer cell lines. Thus, we highly recommend the combination of these two compounds for progression to in vivo translational and clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available